Ndimo Modipane

Ndimo Modipane


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2026 in COVID
Verified
Journal Article
Open access
PDF file
JCJoseph Musonda Chalwe
Joseph Musonda Chalwe
RMRetsilisitsoe Raymond Moholisa
Retsilisitsoe Raymond Moholisa
NMNdimo Modipane
Ndimo Modipane
SMSaidon Mbambara
Saidon Mbambara
RMRelebohile Matobole
Relebohile Matobole
MKMANKGOPO KGATLE
MANKGOPO KGATLE
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19), exploits angiotensin-converting enzyme 2 (ACE2) for cell entry, implicating the renin–angiotensin system (RAS) in disease pathogenesis. Hypertension (HT), a major comorbidity, is strongly influenced by genetic factors within RAS, including angiotensin ii receptor type 1 (AGTR1) and ACE2) polymorphisms. However, data on these variants in African populations remain scarce. This study investigated associations between AGTR1 and ACE2 single-nucleotide polymorphisms (SNPs), HT, and COVID-19 severity in patients at a Tshwane Academic Hospital. Methods: We genotyped AGTR1 and ACE2 SNPs in 94 PCR-confirmed COVID-19 patients using Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry. Clinical data were extracted from hospital records. Ordinal logistic regression models assessed relationships between SNPs, HT, and COVID-19 severity. Results: The cohort (mean age: 53.9 years; HT prevalence: 54.9%) exhibited mild (54.9%), moderate (18.6%), and severe (26.5%) COVID-19. Although the rs2106809 A genotype appeared to be associated with lower odds of severe disease (OR = 0.39, 95% CI: 0.14–1.08, p = 0.04), this observation should be interpreted with caution given the limited sample size of this study. Other SNPs and clinical variables showed no significant associations. Conclusions: This exploratory study represents the first description of AGTR1 and ACE2 SNP patterns in COVID-19 patients from Tshwane. While the rs2106809 variant may indicate a possible protective trend, the evidence remains preliminary. Age correlated with severity. Larger, multi-ethnic studies are needed to confirm these findings.

2 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JCJoseph Musonda Chalwe
Joseph Musonda Chalwe
RMRetsilisitsoe Raymond Moholisa
Retsilisitsoe Raymond Moholisa
NMNdimo Modipane
Ndimo Modipane
SMSaidon Mbambara
Saidon Mbambara
RMRelebohile Matobole
Relebohile Matobole
MKMANKGOPO KGATLE
MANKGOPO KGATLE
Background: Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the causative agent of Coronavirus disease 2019 (COVID-19), exploits the angioten-sin-converting enzyme 2 (ACE2) for cell entry, implicating the renin–angiotensin sys-tem (RAS) in disease pathogenesis. Hypertension (HT), a major comorbidity, is strongly influenced by genetic factors within RAS, including angiotensin ii receptor type 1 (AGTR1) and ACE2) polymorphisms. However, data on these variants in African pop-ulations remain scarce. This study investigated associations between AGTR1 and ACE2 single nucleotide polymorphisms (SNPs), HT, and COVID-19 severity in patients at A Tshwane Academic Hospital. Methods: We genotyped AGTR1 and ACE2 SNPs in 94 PCR-confirmed COVID-19 pa-tients using Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MAL-DI-TOF) mass spectrometry. Clinical data were extracted from hospital records. Ordi-nal logistic regression models assessed relationships between SNPs, HT, and COVID-19 severity. Results: The cohort (mean age 53.9 years; HT prevalence 54.9%) exhibited mild (54.9%), moderate (18.6%), and severe (26.5%) COVID-19. The rs21068092 A genotype was significantly associated with reduced odds of severe disease (OR = 0.39, 95% CI: 0.14–1.08, p = 0.04), suggesting a protective effect. Other SNPs and clinical variables showed no significant associations. Conclusion: This first report on AGTR1 and ACE2 SNP profiles in COVID‑19 patients from Tshwane highlights rs2106809 as a potential protective marker. Age correlated with severity. Larger, multi‑ethnic studies are needed to confirm these findings.